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Clinical evidence is accumulating for a role of the microbiome in contributing to or 
modulating severity of inflammatory diseases. These studies can be organized by various 
organ systems involved, as well as type of study approach utilized, whether investigators 
compared the microbiome of cases versus controls, followed patients longitudinally, or 
intervened with antibiotics, prebiotics, or bacterial introduction. In this review, we sum-
marize the clinical evidence supporting the microbiome as an important mechanism in 
the onset and maintenance of inflammation.
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iNTRODUCTiON
The human body is host to hundreds of thousands of bacteria and other microorganisms, primarily 
colonizing our epithelial surfaces and attaining their highest densities within the lower gastrointes-
tinal tract. These commensals play an important homeostatic role in a variety of our body systems, 
including the immune system, and can have both immune-stimulatory and immune-regulatory 
effects. Intriguingly, microbiota differences have been associated with a variety of inflammatory 
diseases, indicating that targeting or modulating the microbiota may be a novel therapeutic strategy 
that could nicely complement established treatments for inflammatory conditions.
At the extremes of age, humans show changes in microbiome composition. The degree of diversity 
observed in the fecal microbiota is highest at 2  years of age, and the gut microbiota undergoes 
dramatic changes during the first 3 years of life, after which it stabilizes and generally changes only 
slightly throughout adulthood (1). This pattern of early fluctuations in life followed by stabilization 
has been attributed to dietary changes as infants transition from breastfeeding or formula to more 
solid food (2).
After birth, the mode of delivery has been seen to impact on the microbial composition of the 
newborn, with infants born vaginally exhibiting bacterial communities of their own mother’s vaginal 
microbiota, while infants born by cesarean section showed bacterial communities of skin origin 
(1). Moreover, the intestinal microbiota of the mother can shape the bacterial colonization of their 
infant’s gut (3). Even the placenta seems to have a unique microbiome that correlates with those 
found in the oral cavity (4). This may raise a question whether these findings correlate with higher 
chances of preterm deliveries in mothers with periodontal diseases (5) and modulating the oral 
microbiota could potentially prevent such complications during pregnancy.
The Human Microbiome Project was a NIH initiative launched in 2008 on the heels of the 
Human Genome Project that reflected an increasing interest in the study of microbes as complex 
and dynamic communities rather than isolated species. The interdisciplinary collaboration set out 
to characterize the human microbiome and explore the relationship between population fluctuations 
and disease; to establish new computational tools and strategies to complement a resource repository 
for ongoing studies; and to study the ethical, legal, and social implications of the field’s expansion. 
The 5-year initiative accelerated the progress of what had been a nascent discipline and facilitated our 
TABLe 1 | Clinical studies of microbiome associations and interventions in inflammatory conditions.
Condition Longitudinal 
cohort studies
Case–control studies Cross-sectional 
studies
interventional
Inflammatory 
bowel diseases
(14) (n = 227) (61) (n = 31)
Ulcerative colitis (60) (n = 59), (64) (n = 19), (66) (n = 29), (67) (n = 105), (17) 
(n = 120), (18) (n = 327), (19) (n = 120), (20) (n = 100), (21) 
(n = 90), (22) (n = 40), (23) (n = 26), (24) (n = 15), (26) (n = 29), (27) 
(n = 90), (29) (n = 144), (28) (n = 147), (30) (n = 40), (31) (n = 20), 
(32) (n = 30), (33) (n = 30), (34) (n = 32), (68) (n = 18), (69) (n = 41), 
(76) (n = 9), (77) (n = 11), (79) (n = 11), (80) (n = 8), (81) (n = 6), 
(82) (n = 5), (83) (n = 6), (88) (n = 3), (84) (n = 62), (89) (n = 75), (90) 
(n = 48), (78) (n = 1), (85) (n = 1)
Pouchitis (65) (n = 20), (43) (n = 12), (45) (n = 20), (36) (n = 40), (38) (n = 40), 
(37) (n = 36), (39) (n = 31), (41) (n = 43), (42) (n = 16), (40) (n = 31)
Crohn’s disease (15) (n = 38), (16) (n = 21) (59) (n = 22), (62) (n = 10), (63) (n = 103), (46) (n = 20), (47) 
(n = 32), (48) (n = 34), (49) (n = 165), (50) (n = 120), (54) (n = 119), 
(55) (n = 30), (52) (n = 11), (53) (n = 75), (51) (n = 37), (56) (n = 28), 
(57) (n = 98), (58) (n = 70), (70) (n = 30), (71) (n = 10), (72) (n = 4), 
(73) (n = 30), (74) (n = 4), (75) (n = 5), (86) (n = 8), (87) (n = 19)
Multiple sclerosis (132) (n = 78), (133) (n = 67), (134) 
(n = 40), (135) (n = 15), (136) 
(n = 103), (137) (n = 24), (139) 
(n = 61)
(138) (n = 17) (141) (n = 12), (142) (n = 5), (140) (n = 3)
Guillain–Barré 
syndrome
(145) (n = 171), (146) (n = 103), (147) 
(n = 212), (148) (n = 549)
(144) (n = 56)
Fibromyalgia (151) (n = 95), (152) (n = 114), (154) 
(n = 100), (155) (n = 233), (156) 
(n = 1,125), (157) (n = 251), (158) 
(n = 168)
(153) (n = 233)
Systemic lupus 
erythematosus
(161) (n = 40), (162) (n = 35)
Atherosclerosis (98) (n = 2,595), 
(99) (n = 4,007)
(92) (n = 17), (91) (n = 2), (93) 
(n = 49), (96) (n = 7)
Vasculitis (94) (n = 38), (95) (n = 31), (100) 
(n = 17)
Eczema (103) (n = 23)
Scleroderma (112) (n = 4), (110) (n = 80)
Psoriasis (106) (n = 6), (107) (n = 22), (108) 
(n = 9,295)
Rheumatoid 
arthritis
(114) (n = 30), (117) (n = 83), (116) 
(n = 156), (118) (n = 114), (113) 
(n = 212)
(115) (n = 46)
Asthma (121) (n = 321), 
(124) (n = 411), 
(125) (n = 47), 
(126) (n = 319)
(120) (n = 43), (122) (n = 20), (123) 
(n = 51)
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in-depth and multi-omic understanding of human microbiome 
science (6).
This review summarizes clinical studies that have helped to 
elucidate the involvement of the microbiota in inflammatory 
diseases. In addition to describing findings, we have also made 
an effort to provide context regarding numbers of patients and 
types of studies performed in Table 1 to allow the reader to better 
gage the quality of evidence being presented.
STRATeGieS OF GUT MiCROBiOTA 
MODULATiON
Multiple avenues for therapeutic modulation of the micro-
biota have been gleaned from the continued research into 
microbiota–host interactions. Most widely administered are 
probiotics, which can be administered by way of lyophilized or 
live single or combination of bacterial preparations or fermented 
foodstuffs (primarily milk products) containing known active 
cultures. The benefits of both single-strain preparations and 
synergistic bacterial mixtures are loosely attributed to any of 
three mechanisms: (1) interference with the growth or survival 
of pathogenic microorganisms in the gut lumen, (2) improve-
ment of mucosal barrier function or mucosal immune system, 
and (3) influence beyond the gut through the systemic immune 
system and other organs (7). Administration of prebiotics, which 
are non-digestible food ingredients, is designed to enrich native 
beneficial populations. While a number of dietary carbohydrates 
show promise for such use, not all have been formally evaluated 
FiGURe 1 | Current strategies of gut microbiota modulation.
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to meet criteria for classification as a prebiotic compound. Such 
ingredients must (1) be neither hydrolyzed nor absorbed in the 
upper digestive tract, thus ensuring fermentation in the colon, 
(2) be a selective substrate for specific potentially beneficial 
commensal bacteria in the colon, stimulating growth and 
expansion or metabolic activation, and (3) thus be capable of 
effecting beneficial shifts in colonic bacterial communities (8). 
Live microbes are also administered with prebiotic substrates in 
preparations known as synbiotics. In addition to conferring the 
benefits of both probiotics and prebiotics, synbiotics are thought 
to improve the survival of the probiotic organism in the host by 
making its specific fermentable substrate readily available (9). 
In contrast, modulation of the intestinal microbiota has also 
been achieved through selective decontamination with narrow-
spectrum antimicrobials. Removal or attenuation of undesirable 
bacterial species allows for reorganization of other populations 
within existing ecological niches (10). Newer treatment modali-
ties include fecal microbiota transplant (FMT), introducing the 
complete microbial ecology of a healthy donor to restore phyloge-
netic diversity and synergistic function (11), and administration 
of bacterial metabolic byproducts such as short-chain fatty acids 
or conjugated bile acids (12). These strategies are summarized 
in Figure 1.
GASTROiNTeSTiNAL–iNFLAMMATORY 
BOweL DiSeASeS (iBD)
The gastrointestinal tract includes several sites that harbor the 
highest densities of bacterial commensals, and thus much of the 
exploration of the potential of therapeutic modulation of the intes-
tinal microbiota has been focused on patients with disorders of the 
digestive system. In inflammatory bowel disease (IBD), comprised 
largely by Crohn’s disease (CD) and ulcerative colitis (UC), genetic 
susceptibilities are thought to predispose to development of height-
ened immunity against enteral “dysbiosis,” a term used to describe 
a deviation or perturbation from a healthy microbiome (13). In 
patients with UC, inflammation is localized primarily to the colonic 
mucosa, while in CD, discrete portions of the entire gastrointestinal 
tract can be involved, particularly the terminal ileum. Currently, no 
specific microorganism has been implicated in the pathogenesis 
or pathophysiology of IBD, but differences in the abundance and 
biodiversity of the enteric flora of individuals affected by IBD 
have been observed. Twin studies have elucidated the role of the 
microbiota excluding genetic involvement and explored potential 
environmental triggers of disease onset. An examination of twin 
pairs with discordance in their disease status found that risk fac-
tors for IBD included early gastrointestinal infection, implicating 
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a potential role for different subsets of intestinal bacteria in main-
taining or disturbing homeostasis of the gastrointestinal tract (14). 
Furthermore, compared to healthy and concordant twin pairs, 
discordant pairs were more likely to have disparities in microbiome 
parameters (15). An analysis of the mucosa-associated microbiota 
of CD patients identified that a reduction of Firmicutes member 
Faecalibacterium prausnitzii was associated with a higher risk of 
endoscopic and surgical disease recurrence (16). F. prausnitzii 
supernatant also reduced the transcription and secretion of 
pro-inflammatory molecules and mitigated symptom severity in 
murine colitis models both in vitro and in vivo.
Probiotics and UC
There is a sizeable body of research examining the clinical 
effects of introducing single bacterial preparations and probiotic 
mixtures to patients with IBD, overall with variable results on 
disease outcomes. The oral probiotic strain Escherichia coli Nissle 
1917 (EcN) was found to be equivalent over both short-term and 
long-term periods to standard 5-aminosalicylic acid (5-ASA) 
treatment for UC in three controlled studies (17–19), but had 
no benefit when used as an adjunct to ciprofloxacin treatment 
(20). In a double-blind study of 90 patients with UC, EcN enemas 
led to no changes in remission rates of UC between the groups, 
although there was a dose-dependent trend where patients who 
received a higher volume of daily EcN enemas responded best (21). 
A number of other single probiotic species have been studied for 
their ability to induce UC remission, with varying results. Rectal 
administration of Lactobacillus reuteri had a significant effect on 
mucosal cytokines, including increased IL-10 secretion leading 
to remission in 31% of pediatric subjects (22). In contrast neither 
rectal nor oral administration of Lactobacillus casei resulted in 
improvement in clinical activity scores following a 2-month trial, 
although there was a decrease in inflammatory cytokine activity 
and increased secretion of IL-10 seen with oral L. casei (23).
Administration of probiotic product VSL#3, a cocktail of 
eight different bacteria (four species of lactobacilli, three species 
of bifidobacteria, and Streptococcus thermophilus) has been quite 
extensively evaluated in patients with UC and found to have 
some promise for induction and maintenance of remission. An 
open-label study showed significantly decreased disease activity 
and increased mucosal alkaline sphingomyelinase activity, which, 
through hydrolysis of sphingomyelin and resultant ceramide 
production, induces epithelial differentiation and apoptosis 
and can inhibit proliferation (24). Another study found that 
VSL#3 treatment reduced levels of platelet-activating factor, a 
pro-inflammatory compound implicated in the development 
and activity of IBD (25). A randomized controlled trial in the 
pediatric population observed an effect on both induction and 
maintenance of remission over a 1-year period, with significantly 
lower endoscopic and histologic measures of disease activity in 
the treatment group even at time of relapse (26). When adminis-
tered in combination with VSL#3, the 5-ASA prodrug balsalazide, 
formulated for targeted colonic release of 5-ASA, was superior to 
either balsalazide monotherapy or traditional 5-ASA in inducing 
remission (27). Administration of VSL#3 alone resulted in signifi-
cant improvement in both disease parameters and remission rate 
compared to placebo (28). A second VSL#3 study also observed 
a significant decrease in disease activity, although the remission 
rate was not significantly improved compared to placebo (29). 
Finally, a study explored the immunomodulatory effects of the 
mixture by comparing the probiotic to corticosteroid treatment, 
placebo-treated patients, and healthy controls. The authors 
observed that both corticosteroids and VSL#3 enhanced IL-10 
expression in dendritic cells (DCs) and reduced expression 
of TLR-2 and IL-12, although VSL#3 patients showed a non-
significant improvement in clinical responses (30).
Other probiotic mixtures have been evaluated in UC with 
varying success. A randomized placebo-controlled trial studying 
the effects of bifidobacteria-fermented milk on UC observed 
improvement in disease activity, which was associated with sig-
nificant increases in fecal butyrate, propionate, and short-chain 
fatty acid concentrations in the treatment group compared to the 
placebo group (31). A mix of Bifidobacterium species was found 
to positively influence relapse rate and demonstrated a variety 
of anti-inflammatory effects (32). Treatment with a mixture of 
Lactobacillus delbrueckii and Lactobacillus fermentum signifi-
cantly reduced mucosal leukocyte infiltration. Expression of IL-6, 
TNF-α, and NF-κB and fecal calprotectin levels were shown to be 
associated with neutrophil infiltration of intestinal tissues when 
compared to the placebo treatment (33). In contrast, a trial of a 
mixture of Lactobacillus acidophilus and Bifidobacterium animalis 
subsp. lactis, in which no other concomitant UC treatments were 
permitted, found no significant clinical benefit (34).
Probiotics and Pouchitis
Colectomy is a common surgical treatment modality for UC, after 
which pouchitis, or inflammation of the surgically created ileal 
pouch, is a common complication. Pouchitis is clinically associ-
ated with frequent relapses and appears to be linked to intestinal 
bacterial composition given the results of several probiotic 
studies (35).
Mixed probiotic agents, including VSL#3, have been studied 
for efficacy in secondary prevention of pouchitis (36). Among 
patients who underwent probiotic treatment to maintain 
antibiotic-induced remission, only 15% relapsed compared to all 
patients in the control group (p < 0.001). Microbial components 
of the supplement could be detected in fecal samples during the 
trial period, but returned to baseline levels within a month of 
discontinuation, and all remissions relapsed within 4  months 
after completing treatment. These findings were supported by a 
similar study of patients with chronic or relapsing pouchitis (37). 
VSL#3 was also found to prolong time before onset of primary 
pouchitis, which was again correlated with an increase in fecal 
colonization of the probiotic species (38). Treatment has been 
associated with an increase in regulatory T-cells and a decrease 
in expression of pro-inflammatory cytokines in the intestinal 
mucosa of treated subjects (39). However, a study of long-term 
remission maintenance, modeling more realistic use in actual 
clinical practice, found no benefit, and subclinical evidence of 
mild-to-moderate disease was found on endoscopy in the 19% 
who remained in the study for the full 8 months (40).
Other studies of mixed probiotics have been generally positive. 
One study evaluated a subset of VSL#3 components in treatment 
for pouchitis (41). After 9  months of probiotic treatment, the 
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number of patients with pouchitis was reduced when compared 
to the control group, concluding that long-term probiotic use can 
serve as an effective method of pouchitis prevention. Another 
study found that a fermented milk product containing lactobacilli 
and bifidobacteria altered fecal microbiota composition and sig-
nificantly improved superficial measures of pouchitis compared 
to the control (42).
Studies that focus on a single bacterial species have also been 
reported to have some efficacy for pouchitis. A small 6-month 
trial of Bifidobacterium longum found a significant difference in 
clinical, endoscopic, histological disease, and microbiota param-
eters (43). A small double-blind study of Clostridium butyricum 
MIYAIRI found a non-significant trend toward developing 
pouchitis in the placebo group, but endoscopic and microbial 
data were inconclusive (44). In contrast, administration of 
Lactobacillus rhamnosus GG to maintain pouchitis remission 
was ineffective despite shifts in microbial community profiles 
observed during treatment (45).
Probiotics and CD
Compared to the large number of studies performed in patients 
with UC, less evidence exists to support the efficacy of either 
single-strain or multistrain probiotics in inducing or maintain-
ing remission in patients with CD. Several small randomized 
controlled trials of Saccharomyces boulardii observed significant 
reduction in symptoms (46), significant effect on relapse rate (47), 
and decreased intestinal permeability (48); however, a 52-week 
trial of 165 patients found no effect of the yeast on either latency 
to relapse or relapse rate (49). VSL#3 was found in one study 
to display a trend toward benefit in maintenance of surgical 
remission, as well as significant reduction in IL-1β, TNF-α, and 
IFN-γ and increase in TGF-β, which correlated with decreased 
endoscopic disease activity (50). Several other studies of VSL#3, 
however, found no significant effect of the supplement on relapse 
rate or cytokine profiles (51–54) and one investigation found 
administration to be associated with an increase in symptom 
flares (55). Other trials of single-species probiotics were similarly 
unencouraging, with EcN administration over a 1-year mainte-
nance period demonstrating a non-significant trend to benefit 
(56), and two large trials of Lactobacillus johnsonii demonstrating 
no effect on disease activity or recurrence (57, 58).
Prebiotics and iBD
Dietary interventions designed to provide intestinal bacteria 
with metabolic substrates are termed prebiotics and can include 
fibers, resistant starches that are difficult for the small intestine 
to completely digest, and poorly absorbed monosaccharides, 
oligosaccharides, and polysaccharides. A study of CD patients 
asked subjects to quickly transition from a low-residue diet that 
is commonly recommended for IBD to a high-fiber diet rich in 
vegetables and found that all achieved disease remission within 
2  months, which was sustained in 92% of patients at 2  years 
without scheduled maintenance pharmaceutical therapy (59). 
Another study found promising results with germinated barley 
foodstuff for maintenance of remission and potentially decreased 
steroid burden with reduced risk of relapse (60). In contrast, 
lactulose had no significant effect on clinical, endoscopic, or 
immunohistochemical parameters in either UC or CD (61). 
Fructooligosaccharide (FOS) supplementation, however, during 
active CD increased the abundance of fecal bifidobacteria and 
also led to increased secretion of IL-10 by intestinal DCs (62). 
A subsequent randomized, double-blind trial of FOS compared 
to a placebo for 4 weeks found a similar augmentation of IL-10 
production by DCs, but unfortunately neither significant clini-
cal benefit nor differences in fecal concentration of potentially 
beneficial commensals were found (63). Another study of FOS 
in combination with inulin found no change in inflammatory 
mediators IL-8 and PGE-2 or disease activity, but there was a sig-
nificant reduction in calprotectin levels (64). Administration of 
single-agent inulin to patients with pouchitis reduced Bacteroides 
fragilis concentration in feces, increased fecal butyrate concentra-
tions, and attenuated pouchitis disease activity index (65). Finally, 
prebiotic maintenance treatment of UC with Plantago ovata, also 
known as psyllium, was found to be more effective than placebo 
over 4  months (66), but was no better than traditional 5-ASA 
treatment in a long-term study of 1 year (67).
Synbiotics and iBD
The results of trials with synbiotics, or matched combinations 
of probiotics and prebiotics, in the management of IBD have 
been inconsistent. In UC, a randomized controlled study of 
B. longum + FOS +  inulin demonstrated no significant disease 
mitigation (68); however, bifidobacteria  +  galactooligosac-
charide significantly reduced endoscopic disease parameters, 
as well as levels of fecal Bacteroidaceae (69). A 2-year study in 
CD patients on the efficacy of synbiotics for maintaining surgical 
remission found no effect on any disease parameters, although 
the trial ended prematurely due to poor enrollment (70).
FMT and iBD
Fecal microbiota transplant has gained traction as a successful 
therapy for chronic, recurrent, or resistant Clostridium difficile 
infection. Although the pathophysiology of IBD is likely more 
complex than that of C. difficile infection, several case and cohort 
studies and two randomized controlled trials have begun the 
investigation of FMT as a treatment methodology. We have 
divided our summary of these studies into single-arm studies 
with either upper or lower introduction approaches, followed by 
controlled studies.
Single-arm studies of upper FMT introduction have been 
reported. Two studies in CD patients looked at the effects of 
nasogastric or gastroscopic FMT administration over a follow-
up period of 1–3  months. FMT administration in a pediatric 
cohort induced remission within 2 weeks in 7 of 10 patients, all 
of whom demonstrated microbial engraftment, and remission 
was sustained by 5 patients at 6 weeks (71). However, a second 
pediatric study of an additional four patients by the same group 
found the same procedure to have no effect over the 3-month 
trial period (72). In a larger study of 30 patients receiving 1–3 
treatments, clinical improvement and steroid-free maintenance 
were observed in 8 patients and a complete remission in another 
4 patients (73). However, series of three nasojejunal transplants 
in four CD patients was associated with only transient changes in 
microbiota composition and no improvement in symptoms (74), 
6Slingerland et al. Microbiome in Inflammatory Diseases
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 400
while a second trial of nasojejunal in five UC patients reported 
only one instance of clinical improvement at the end of 12 weeks 
and the deterioration of two subjects within a month (75).
Single-arm studies of lower FMT introduction have also 
been reported for UC. Treatment with a series of five once-daily 
transplants induced remission that was sustained throughout the 
month-long trial period in three of nine subjects, and clinical 
response was observed in another five patients by the conclusion 
of the trial (76). A study of single transplants in 11 patients showed 
a benefit in both disease activity and quality of life measures at 
the end of 4 weeks (77). A case report of a patient with steroid-
dependent UC who was treated shortly after primary onset of the 
disease reported that a series of 3 transplants 4–6  weeks apart 
led to complete mucosal healing (78), and a case series of 11 
patients similarly observed reductions in disease activity in all 11 
patients (79). In a trial of eight patients, two achieved remission 
after 2 weeks and another by the end of the 12-week period, while 
four others showed clinical improvement (80). Six of six patients 
demonstrated clinical improvement within 2  weeks of a single 
transplant, with sustained improvement at 3 months observed in 
two patients (81). The group also reported a shift in fecal micro-
bial profile toward donor structure in three patients, although 
evidence of a shift did not correlate with symptomatic response. 
Another study of single transplants in UC patients surprisingly 
noted no correlation between microbial engraftment and clinical 
response to therapy, but nevertheless observed response in three 
of five subjects (82). A subsequent 3-month study by the same 
group noted remission in only one of six patients at the 1-month 
time point, and all patients displayed worsening symptoms by 
the end of the trial (83). Again, achieving remission was not 
associated with success of donor flora engraftment; interestingly, 
however, loss of similarity achieved over time did correlate with 
the reemergence of disease activity. Finally, a single-institutional 
review of all FMTs administered to UC patients found that 
complete clinical remission was observed in 42 of 62 patients and 
partial response and failure in 15 and 5 patients, respectively (84). 
This group has also described a case of complete and unexpected 
reversal of concomitant immune-mediated thrombocytopenia, 
as well as gastrointestinal symptom attenuation, in a woman 
undergoing the procedure in an effort to control her chronic, 
relapsing disease (85).
Single-arm studies of lower FMT in CD patients have also been 
performed. Two single-transplant studies conducted showed pre-
liminary promise for CD patients, with one showing remission in 
half of the 8 subjects after 2 months (86) and the other reporting 
response in 11 of 19 subjects (87), over half had maintained their 
stability at 12  months, although 7 experienced a worsening of 
symptoms. They also noted significant species-level similarity 
between donor and recipient in responders compared to non-
responders, as well as increased microbial diversity. A small study 
of the long-term effects of colorectal FMT was carried out in 3 
patients, who received a tapering course of 22–30 transplants over 
6–12 weeks (88). All three achieved immunotherapy-free remis-
sion for over 2 months until symptom return motivated a return 
to conventional therapies.
Finally, two controlled studies of FMT for UC have been 
reported with opposing results. One trial randomized 75 UC 
patients to receive either 6  weekly FMTs or water enemas and 
found that those in the treatment group had a superior rate of 
achieving remission (89). Greater efficacy was seen in those patients 
who had been diagnosed within a year, perhaps indicating an 
association between outcome and degree of mucosal damage. 
Interestingly, the source of FMT may be an important factor, 
stool from one of six donors induced remission in nearly 40% 
of recipients, significantly higher than the 10% achieved by 
each of the other five donors. In contrast, a study of 48 patients 
randomized individuals to receive two nasoduodenal FMTs from 
either healthy donors or their own stool and found no significant 
differences between the treatment and placebo groups (90). The 
conflicting results of these two studies could be attributed to a 
number of differences in methodology, including site of admin-
istration (upper versus lower gastrointestinal tract introduction), 
type of control treatment, and number of treatments per patient, 
and so to date, the efficacy of FMT for UC and IBD in general 
remains to be fully elucidated.
Overall, clinical and microbial responses to FMT in patients 
with IBD appear to be mixed and when positive unfortunately 
are often transient. A handful of impressive clinical responses, 
however, have been reported. As the bulk of the studies thus far 
have been small, short, and uncontrolled, further research into 
optimal donor and patient characteristics, exploration of under-
lying immunomodulatory mechanisms, and substantiation of 
long-term efficacy are warranted.
CiRCULATORY
Many studies have investigated the role of microorganisms in the 
pathophysiology of vascular inflammatory conditions, including 
atherosclerosis (91, 92), aortic aneurysms (93), and systemic 
vasculitides such as Behçet’s syndrome (94) and polyarteritis 
nodosa (95). Several studies have identified bacteria within the 
diseased vasculature, primarily in the setting of atherosclerosis, 
while derangements in intestinal bacterial composition have been 
seen in patients with systemic vasculitis.
Atherosclerosis
Inflammation is an important contributor to the pathogenesis of 
atherosclerosis. Thought to arise from endothelial dysfunction, 
the resulting inflammation in the form of an accumulation of 
macrophages leads to deposition of low-density lipoproteins 
and eventual formation of fatty streaks. A role for bacteria in the 
pathogenesis of atherosclerosis was identified when the respira-
tory tract pathogen Chlamydia pneumoniae was detected within 
atherosclerotic vessels (96). Interestingly, infection of macrophage 
precursors (monocytes) by C. pneumoniae increased their adher-
ence to endothelium, and chlamydial lipopolysaccharide was 
considered a key player in this process (97). T  cell responses 
against C. pneumoniae have also been demonstrated within 
atherosclerotic plaques (92), suggesting an additional potential 
contribution from the adaptive immune system. Besides C. pneu-
moniae, other bacteria such as Porphyromonas gingivalis have 
also been implicated in the inflammatory process that leads to 
atherosclerosis (91). More recently, the intestinal microbiota have 
been implicated in the pathogenesis of atherosclerosis by altering 
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the metabolism of ingested dietary compounds. l-carnitine, a 
trimethylamine and a compound found in red meat, is metabo-
lized by intestinal bacteria to trimethylamine N-oxide (TMAO), 
which was found in higher concentrations in non-vegan humans 
than in vegans (98). TMAO was found to enhance calcium release 
from platelets stores in response to various stimuli, thus increas-
ing their thrombogenic activity and accelerating atherosclerosis 
in animal models (99).
vasculitis
Many systemic vascular diseases have been historically associated 
with a specific microorganism; an example is the link between 
polyarteritis nodosa and hepatitis C virus (95). Another systemic 
vasculitic disease, Behçet syndrome, may have an intestinal 
microbiota contribution to its pathogenesis. Patients with Behçet 
syndrome have a significant dysbiosis of their gut microbiota and 
also a decrease in the short-chain fatty acid bacterial metabolite 
butyrate compared to healthy controls (94). Giant cell arteritis 
has been found to be associated with several viruses and bacteria, 
but a recent unbiased DNA sequencing study of temporal artery 
biopsy samples was unable to confirm these associations (100).
iNTeGUMeNTARY
The skin is the largest organ in the body. In addition to providing 
barrier function, it also harbors a reservoir of numerous popula-
tions of microbiota. Recent advances in molecular approaches 
toward culturing microbiota on the skin have revealed a huge 
topographical variability of skin microbiota (101). Researchers 
have begun to examine this variability and determine whether 
it could contribute to a predilection for developing certain skin 
conditions at particular body sites, for example, psoriasis tends 
to affect hairy scalp and extensor surfaces, while eczema tends to 
affect flexor surfaces.
Atopic Dermatitis (AD)
Atopic dermatitis, also known as eczema, is a common chronic 
inflammatory skin disease characterized by frequent flares of 
inflammation with subsequent pruritus, dryness, and scaling. 
Two mechanisms were historically hypothesized to explain 
eczema: one mechanism considers the trigger an epithelial bar-
rier dysfunction secondary to an intrinsic defect in epithelial cells 
and the other mechanism suggests that IgE sensitization occurs 
secondary to an immunological disturbance and inflammation, 
which then leads to epithelial barrier dysfunction (102).
Recent studies have revealed a relationship between the sever-
ity of AD flares and the type of bacterial communities colonizing 
the skin and overall diversity (103). A longitudinal examination 
of antecubital and the popliteal regions of children with eczema 
found that diversity was significantly lower during the no-
treatment flares, and Staphylococcus aureus was the predominant 
bacteria, while there was no significant difference in diversity 
during the baseline, intermittent treatment, postflare, and con-
trols. These findings suggest that dysbiosis of skin microbiota 
occurs during AD, although whether this dysbiosis contributed 
to inflammation remains unclear. Interestingly, however, treat-
ment of AD with topical steroids and antimicrobials resulted 
in restoration of bacterial diversity by decreasing S. aureus 
predominance in favor of Streptococcus, Corynebacterium, and 
Propionibacterium species.
The initial mechanisms or triggers that induce inflammation 
in AD are unknown. Some evidence suggests that AD may begin 
independently of IgE and that IgE-mediated sensitization occurs 
after the first lesion appears (102). Mast cell degranulation occurs 
after the development of antigen-specific IgE. S. aureus produces 
several toxins, including alpha toxin that targets cell membranes 
and induces mast cell degranulation, supporting a potential 
immunological link between S. aureus colonization and develop-
ment of AD (104).
Psoriasis
Psoriasis is an inflammatory skin disorder characterized by 
hyperproliferation of keratinocytes. This is thought to be a response 
to an unknown trigger with possible interactions between the host 
microbiota and the immune system (105). One study examined 
the difference in bacterial composition between psoriatic lesions, 
unaffected skin of psoriatic patients, and healthy participants 
using the 16S rDNA PCR on skin swabs (106). In contrast to 
normal participants and healthy skin samples of psoriatic patients 
where Actinobacteria (predominately Propionibacterium acne) 
were the most abundant and diverse, psoriatic lesions showed 
an abundance of Firmicutes such as Streptococcus. Similarly, 
Proteobacteria were detected less frequently in psoriatic lesions 
compared to healthy controls. A related study of skin biopsies 
found a similar loss of Propionibacterium and an increased 
abundance of Streptococcus and Staphylococcus in psoriatic 
lesions (107). However, unlike the swab study described above, 
Proteobacteria in biopsies were found at much higher levels in 
psoriatic lesions than in controls.
A weak association between development of psoriasis and 
preceding antibiotics has been reported, potentially indicating 
a link between microbiota perturbation and disease. However, 
in this study, a history of prior skin infections was also associ-
ated with having a diagnosis of disease regardless of whether 
patients received antibiotics, leading the authors to conclude that 
infections could be associated with the development of pediatric 
psoriasis but antibiotics do not appear to contribute substantially 
to that risk (108). An additional caveat includes the possibility 
that misdiagnoses of skin infections were occurring in children at 
times prior to the making of a clear diagnosis of psoriasis.
Systemic Sclerosis (SSc) (Scleroderma)
The hallmark of SSc is pathological fibrosis of skin and internal 
organs, which is thought to arise from abnormalities in the vascular 
and immune system. An autoimmune disease that typically affects 
middle-aged women, SSc can also occur in men and children. Its 
pathogenesis is multifactorial and includes genetic, autoimmune, 
and environmental factors. The presence of autoantibodies further 
supports the autoimmunity aspect of this disease and are utilized 
in categorizing SSc into diffuse and limited forms. However, to 
date, there is no animal model of SSc that successfully induces 
the disease by immunization against a specific autoantigen or via 
transfer of immune cells. Thus, the role of the immune system in 
the pathogenesis of this disease remains unclear (109).
8Slingerland et al. Microbiome in Inflammatory Diseases
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 400
Infectious agents that have been previously shown to be 
associated with the pathogenesis of SSc include parvovirus B19, 
Epstein–Barr virus, endogenous retroviruses, Helicobacter pylori, 
and chlamydial species (110, 111). In addition, antibodies against 
cytomegalovirus, hepatitis B virus, and toxoplasmosis have been 
detected at higher frequencies in patients with SSc, suggesting a 
role for these infectious agents in the initiation or progression 
of disease (110). It remains unknown whether the association 
between SSc and infectious agents is causal or if, alternatively, the 
immune system in these patients is altered leading to increased 
exposure to microorganisms.
Rhodotorula glutinis, a member of the fungal microbiome, was 
found to be overrepresented in the skin of a subset of SSc patients 
with an early diffuse presentation subtype (112). An environmen-
tal yeast that is known to cause fibrosis in the setting of opportun-
istic infections such as dialysis-associated fungemia, Rhodotorula 
has been hypothesized to contribute to inflammation-mediated 
fibrosis in this subset of SSc patients.
Although neither the mechanisms nor the pathogens respon-
sible for the development of SSc have been definitively proven 
(111), four potential mechanisms have been studied: (1) molecular 
mimicry that may induce antibody production against vascular 
antigens, (2) endothelial cell damage that could be mediated by 
the direct toxic effects of the microorganisms or as a reaction of 
immune response against them, (3) superantigens derived from 
bacteria, and (4) microchimerism, where the presence of cells or 
DNA can be found in an individual but originated from a differ-
ent organism (most commonly a fetus), and patients with diffuse 
SSc have been found to harbor more CD4+ microchimeric T cells 
than controls (111).
MUSCULOSKeLeTAL
Rheumatoid Arthritis (RA)
Of the various arthritic diseases, a relationship with the micro-
biome has been best characterized in patients with RA. RA is a 
systemic disease that affects multiple organs at different stages. 
Thus, studies of dysbiosis of the microbiota in RA patients have 
focused on a variety of sites to better understand its multisystemic 
manifestations. One study examined the bacterial composition of 
oral (dental and salivary) and fecal samples in patients with RA in 
comparison to healthy controls (113). Notably, RA patients were 
noted to have both oral and fecal flora that were distinct from 
that of controls, characterized by reduced Haemophilus spp. and 
increased Lactobacillus salivarius. The increase in L. salivarius 
could be interpreted as consistent with a prior study that found 
increased and more diversity in bacteria from the Lactobacillus 
genus in RA patients, including L. salivarius (114). However, not 
all lactobacilli may be pro-inflammatory in the setting of RA, as 
an interventional study with L. casei capsules showed reduced 
inflammation and improved severity of disease in patients receiv-
ing the probiotic (115). RA patients also had generally an increase 
in Gram-positive bacteria in the intestinal tract compared to 
controls, as well as an increased in oral anaerobic bacteria. 
Interestingly, levels of anticitrullinated protein autoantibodies, 
which are used in the clinical diagnosis of RA, were positively 
correlated with oral Actinomyces spp. and negatively correlated 
with oral Haemophilus spp. (113).
Porphyromonas gingivalis has also been reported to be 
associated with RA severity, although results have been mixed. 
P. gingivalis DNA was significantly more likely to be found in 
the synovial fluid of patients with RA than in controls (116), and 
interestingly the severity of periodontal disease (quantified by the 
number of missing teeth) in patients with RA was positively cor-
related with the number of affected joints. However, another study 
found only an association between P. gingivalis and the likelihood 
of developing and severity of periodontitis but no association 
with RA (117), and a third study found that P. gingivalis was more 
abundant in the oral cavity of controls compared to cases (113).
Prevotella copri has been linked with disease activity in RA 
patients (118). It was found in increased abundance in fecal 
samples from untreated newly diagnosed RA patients, while both 
treated chronic RA patients and controls had reduced amounts. 
The study went on to identify Prevotella-derived genes that were 
also associated with disease activity and also demonstrated exac-
erbation of disease by P. copri in a murine model of colitis. Thus, 
intestinal P. copri appears to exacerbate inflammation and may be 
a viable target in patients with autoimmunity.
ReSPiRATORY
Asthma
Asthma has been described as a triad of airflow obstruction, bron-
chial hyperresponsiveness, and lower airway inflammation. The 
inflammatory trigger is thought to be multifactorial, although in 
genetically susceptible individuals, the immune system has been 
particularly implicated, specifically in the way it interacts with 
environment exposures (119). Both airway and intestinal sites of 
commensal bacteria have been associated with asthma outcomes. 
Respiratory airways are not sterile and in fact harbor significant 
populations of microbiota. Changes in the composition of airway 
bacteria have been found to be associated with asthma and 
emphysema, as well as with exacerbations of these diseases (120).
In a prospective cohort study, culture-based assays of the 
hypopharynx found that asymptomatic neonates at 1 month of age 
who were colonized with Streptococcus pneumoniae, Hemophilus 
influenzae, or Moraxella catarrhalis, or a combination of these 
organisms, were more likely to have manifestations of asthma at 
5 years of age (121). Hemophilus and other Proteobacteria have 
also been implicated in studies comparing the airway flora of 
asthma patients with controls that utilized sequencing-based 
approaches (120, 122) and have been associated with more severe 
(corticosteroid-refractory) disease (123). Whether colonization 
with these organisms can help cause asthma, and potential mech-
anisms for how they may do this, remains to be fully explored.
The intestinal microbiome may also help contribute to asthma 
or other allergic diseases, particularly early life exposures to 
intestinal dysbiosis, although each study has had slight incon-
sistencies. In a large study of over 400 infants, intestinal flora 
diversity in the first year of life was associated with protection 
from development of allergic sensitization, allergic rhinitis, and 
peripheral blood eosinophilia, but not asthma or AD (124). In 
contrast, a smaller study of just fewer than 50 infants found that 
samples collected within 1 month of age showed that intestinal 
flora diversity was associated with protection from later develop-
ment of asthma, but was not associated with protection from 
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other allergic manifestations (125). A third recent study of over 
300 children who were at a higher risk for developing asthma 
was able to identify 4 bacteria taxa that were associated with 
protection in the first 100 days of life: Lachnospira, Veillonella, 
Faecalibacterium, and Rothia. An examination of urinary and 
fecal metabolites found that reduced urinary urobilinogen and 
increased fecal acetate were also associated with protection, sug-
gesting that bacterial involvement in the metabolism of bile and 
short-chain fatty acids could be contributing to modulation of 
asthmatic risk. Interestingly, administering a cocktail of bacteria 
from these taxa led to reduced disease severity in a gnotobiotic 
mouse model of asthma, providing additional evidence for poten-
tial causality (126).
NeUROMUSCULAR
A potential interaction between the nervous system and the gut 
has only recently expanded to incorporate enteric flora (127). While 
the preponderance of current research is preclinical, knowledge of 
the gut–brain axis and the underlying neurologic, immunologic, 
and endocrine processes that facilitate communication between 
the two distal sites, as well an increasing understanding of the 
central role of the microbiome in intraintestinal and extraintesti-
nal immunity, have indicated probable microbial involvement in 
human neuromuscular disorders such as multiple sclerosis (MS), 
Guillain–Barré syndrome (GBS), and fibromyalgia (FM).
Both MS and GBS are demyelinating diseases; MS is character-
ized by a vast range of neurological symptoms stemming from dam-
age to the central nervous system (CNS) (128) and GBS presenting 
as rapid-onset sensory changes and ascending muscle weakness 
as a result of damage to peripheral nerve cells (129). Although 
MS has also been linked to genetic variation (130), both MS and 
GBS are thought to occur in large part due to environmentally 
acquired triggers that catalyze autoimmunity (128, 129). However, 
a murine model of MS has demonstrated a role for commensal 
enteric flora to drive T cell responses against a myelin autoantigen 
in gut-associated lymphoid tissue, which then condition and drive 
proliferation of antigen-specific B cells, resulting in spontaneous 
autoimmune demyelination (131). This demonstration of the 
immunomodulatory contribution of the gut flora in the patho-
genesis of CNS disorders, as well as clinical evidence of dysbiosis 
or infection associated with MS and GBS, supports exploration of 
potential prognostic biomarkers in the microbiota as well as the 
effects of therapeutic microbial intervention.
Multiple Sclerosis
Compared to healthy controls, the flora of patients with MS is 
notable for a relative decrease in bacteria belonging to Clostridia 
and Bacteroidetes (132, 133), as well as an overall decrease in 
species richness in relapse-remitting (RRMS) patients. RRMS 
was further associated with significant intestinal permeability as 
measured by lactulose/mannitol urinary ratio (134). A different 
study of vitamin D therapy for MS found an increase in abun-
dance of Akkermansia, Faecalibacterium, and Coprococcus genera 
in patients with previously untreated MS (135). Because strains 
of Faecalibacterium and Coprococcus are producers of the anti-
inflammatory short-chain fatty acid butyrate, and experimental 
colonization with Akkermansia implicated members of the genera 
in immune tolerance of commensal gut microbes, these results 
suggested that intestinal bacterial shifts could help mediate 
beneficial effects of vitamin D therapy in MS patients. Intestinal 
dysbiosis has also been associated with modulation of gene expres-
sion in several immune cell populations, including maturation of 
DCs and activation of T cell and monocytes (136). A pediatric 
study of patients within 2 years of primary disease onset observed 
two associations between abundance of a bacterial subset and an 
immune parameter that were seen in the control cohort but not 
the case population (137). Fusobacteria was strongly positively 
associated with Tregs, and Firmicutes abundance was inversely 
associated with pro-inflammatory Th1. A prior study by the 
same group observed a significant inverse relationship between 
Fusobacteria abundance and MS relapse risk (138).
Pathogenic bacteria have also been reported to be associ-
ated with development or maintenance of MS. In one patient, 
Clostridium perfringens type B colonization could be detected 
shortly after primary disease onset and was associated with 
actively enhancing lesions on brain MRI (139). The group found 
evidence that epsilon toxin (ETX), secreted by C. perfringens, 
disrupts the blood–brain barrier and selectively binds to CNS 
myelin and white matter, which supports its involvement in 
lesion formation. Although identified only in a small minority 
of samples, possibly due to known difficulties in maintaining 
humoral ETX immunity, reactivity to ETX was found to be 10 
times more prevalent in patients with MS versus healthy controls. 
While this is the only known report of C. perfringens type B in a 
human, the human commensal type A was found in significantly 
more healthy controls than in MS patients, suggesting that the 
absence of this commensal could lead to an open ecological niche 
for non-commensal C. perfringens toxinotypes.
A few studies have reported efforts at microbial modulation 
in the treatment of MS. One three-patient series found that FMT 
performed to address MS-associated constipation resulted in 
progressive improvement of neurological symptoms and eventual 
sustained remission (140). Two small studies treated RRMS 
orally with ova from the non-pathogenic helminth Trichuris suis  
(141, 142), which has been successfully applied in cases of IBD. 
Both studies observed that T. suis was associated with an increase 
in anti-inflammatory and immunoregulatory serum cytokines and 
a decrease in MRI-detectable brain lesions. In addition to its docu-
mented immunomodulatory effects, helminth colonization was also 
associated with greater fecal species richness in an otherwise healthy 
population (143), although the microbiome was not examined in 
these trials. This is evidence that the correlated clinical improve-
ment could be effected directly by the organism or indirectly by 
alterations in community structure and humoral immunity.
Guillain–Barré Syndrome
The presence of pathogenic bacteria at disease onset is particularly 
associated with GBS, in which approximately 30–40% of patients 
show serological evidence of recent infection with Campylobacter 
jejuni (144–148). Many C. jejuni-positive patients demonstrate 
signs of enteric infection just prior to onset of neuropathy with 
the median interval of 9 days to onset of neurological symptoms 
(147). The latency period suggests that GBS may not be the 
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direct effect of the pathogen or its toxins but rather could result 
from a mounted immune response against its presence. Current 
understanding of infection-associated dysbiosis (149) thus lends 
additional support to the role of the microbiota in demyelinating 
diseases.
Fibromyalgia
The etiology of FM is less understood, but hypothesized to 
involve aberrations in the processing of pain signals, resulting in 
chronic diffuse pain and stiffness (150). An increase in serum 
IL-6 and IL-8 has been reported in FM patients, the concentra-
tions of which were positively correlated to duration of disease 
(151). Although no comparisons of healthy and FM microbial 
community structure have been reported, intestinal permeability 
was significantly increased compared to controls in a cohort of 
40 FM patients (p <  0.0003), suggesting that luminal antigens 
may be able to access and modulate immunocompetent cells as 
seen in the hepatic disorders detailed above (152). Furthermore, 
FM is often comorbid with IBD (153), IBS (154–158), and SIBO 
(158). Lactulose breath test administration to diagnose SIBO 
demonstrated abnormal results more commonly in FM patients 
than in controls, and the degree of somatic pain was significantly 
correlated with breath test hydrogen level, supporting further 
exploration of the dynamics of the enteric flora and FM.
SYSTeMiC
Systemic Lupus erythematosus (SLe)
The hypothesized pathogenesis of SLE is similar to that of the 
other autoimmune diseases discussed herein, with genetic, hor-
monal, endocrine, and environmental factors all thought to play a 
role (159). SLE is associated with the largest number of detectable 
antibodies, resulting in the involvement of nearly every organ 
and a diversity of clinical manifestations (160). SLE-associated 
dysbiosis has been characterized in a few studies, highlighting 
changes in community structure, metabolics, and gene expres-
sion. SLE patients have been noted to have a relative increase in 
intestinal Bacteroidetes, resulting in a significant decrease in the 
Firmicutes/Bacteroidetes ratio (161). This was associated with a 
functional increase along oxidative phosphorylation pathways, 
suggesting possible compensatory adaptations to intestinal 
oxidative stress underlying the observed changes in community 
structure. Intestinal metabolomic analysis of SLE patients com-
pared to controls found alterations in mediators of cell signaling, 
quorum sensing, and cell wall synthesis (162), and it was recently 
reported that dysbiotic microbiota from SLE patients elicited dif-
ferent in vitro immune responses from naive CD4+ lymphocytes 
than exposure to microbiota from healthy controls, promoting 
greater lymphocyte activation and Th17 differentiation (163). 
This response has the potential to exacerbate and sustain preexist-
ing inflammation linked to the disease, which could therefore be 
mitigated by restoration of a balanced flora.
Graft-versus-Host Disease (GvHD)
Graft-versus-host disease is an immune-mediated condition that 
commonly occurs in patients who have undergone allogeneic 
hematopoietic cell transplantation (HSCT), a procedure that can 
mediate curative long-term remissions for many hematological 
malignancies as well as benign hematological conditions. The 
presentation of GVHD can be largely categorized into two forms, 
acute and chronic, with acute GVHD often occurring within the 
first 3 months and typically affecting the skin, liver, gastrointes-
tinal, and hematopoietic systems, while chronic GVHD typically 
occurs beyond the first 3 months and can present with a variety 
of manifestations including exocrine dysfunction and systemic 
fibrosis. Whether chronic GVHD may be associated with changes 
in the microbiome has not been well investigated. Acute GVHD, 
however, has long been thought to be strongly modulated by the 
microbiome, particularly intestinal bacteria. Based on animal stud-
ies that indicated intestinal bacteria contributed to acute GVHD, a 
randomized study in the early 1980s of protective isolation includ-
ing gut-decontaminating antibiotics and skin disinfection showed 
a benefit with reduced acute GVHD (164). However, later studies 
did not reproduce this finding, possibly due to inconsistent success 
of gut decontamination (165). As a result, improved pharmacologic 
prevention of GVHD, particularly with calcinuerin inhibitors, has 
largely replaced gut decontamination for GVHD prophylaxis, 
though one clinical trial did demonstrate a benefit for suppress-
ing intestinal obligate anaerobes with metronidazole (166). More 
recent efforts have re-examined the relationship between intestinal 
bacteria and acute GVHD using culture-free methods such as 16S 
deep sequencing. Development of acute GVHD produces striking 
changes in patient intestinal bacterial composition (167–170). 
Furthermore, microbiota damage either prior to HSCT (169) or 
early post-HSCT (171, 172) may increase the subsequent risk of 
developing GVHD. Much of this microbiota damage is mani-
fested as loss of Blautia and other Clostridia (171, 172) or loss of 
Bacteroidetes (169). Perhaps not surprisingly, antibiotics are a 
common cause of microbiota damage in this patient population, 
and treatment with piperacillin-tazobactam (173), carbapenems 
(173), metronidazole (174), and clindamycin (170) have all been 
identified as associated with increased acute GVHD. Given these 
results, interest is building in targeting the microbiota for either 
the prophylaxis or treatment GVHD. A study of daily Lactobacillus 
plantarum administration in pediatric HSCT patients was found 
to be safe and well tolerated, even in the setting of neutropenia. 
In addition, a study of fecal transplantation as therapy for acute 
GVHD was recently reported, with three of four patients have a 
complete response and the last patient having a partial response, 
an overall promising result in the steroid-refractory setting, which 
typically has a poor prognosis (175).
CONCLUSiON
The causes of inflammatory diseases are multifactorial and 
include age, genetics, and environment. Microorganisms are 
crucial in maintaining gastrointestinal homeostasis and can 
potently modulate systemic immunity, and differences in the 
microbiota have been observed in patients with inflammatory 
diseases compared to healthy controls. There is a growing amount 
of clinical research being done to better understand the role that 
the microbial community can play in inflammatory diseases, and 
some progress has been made evaluating the effects of target-
ing the microbiome, particularly in the setting of IBD. Some 
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intriguing responses suggest that this may be a viable strategy, 
but conflicting and inconsistent results leave open questions. One 
possibility may be that patient disease heterogeneity is a source 
of statistical noise, and it is likely that in a subset of patients with 
inflammatory conditions, alterations in the microbiome contrib-
ute significantly to drive disease pathogenesis and maintenance, 
while for other patients, the microbiome may be only a minor 
contributing factor. Developing strategies to distinguish these 
patient subsets will likely be critical to advancing the growing 
field of clinically targeting the microbiome for patients with 
inflammatory diseases.
AUTHOR CONTRiBUTiONS
AES, ZS, and RRJ wrote the manuscript. DHW prepared the 
table. All authors revised the manuscript and approved it for 
publication. AES and ZS have contributed equally to this work.
FUNDiNG
This article was funded by NIH/NHLBI R01 HL124112 (RRJ) and 
the Recruitment of Rising Stars Program, Cancer Prevention and 
Research Institute of Texas (RRJ).
ReFeReNCeS
1. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, 
Fierer N, et  al. Delivery mode shapes the acquisition and structure of the 
initial microbiota across multiple body habitats in newborns. Proc Natl Acad 
Sci U S A (2010) 107:11971–5. doi:10.1073/pnas.1002601107 
2. Avershina E, Storro O, Oien T, Johnsen R, Pope P, Rudi K. Major faecal 
microbiota shifts in composition and diversity with age in a geographically 
restricted cohort of mothers and their children. FEMS Microbiol Ecol (2014) 
87:280–90. doi:10.1111/1574-6941.12223 
3. Gronlund MM, Grzeskowiak L, Isolauri E, Salminen S. Influence of mother’s 
intestinal microbiota on gut colonization in the infant. Gut Microbes (2011) 
2:227–33. doi:10.4161/gmic.2.4.16799 
4. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta 
harbors a unique microbiome. Sci Transl Med (2014) 6:237ra65. doi:10.1126/
scitranslmed.3008599 
5. Baskaradoss JK, Geevarghese A, Kutty VR. Maternal periodontal status 
and preterm delivery: a hospital based case-control study. J Periodontal Res 
(2011) 46:542–9. doi:10.1111/j.1600-0765.2011.01371.x 
6. Human Microbiome Project Consortium. A framework for human micro-
biome research. Nature (2012) 486:215–21. doi:10.1038/nature11209 
7. Rijkers GT, Bengmark S, Enck P, Haller D, Herz U, Kalliomaki M, et  al. 
Guidance for substantiating the evidence for beneficial effects of probiotics: 
current status and recommendations for future research. J Nutr (2010) 
140:671S–6S. doi:10.3945/jn.109.113779 
8. Roberfroid M. Prebiotics: the concept revisited. J Nutr (2007) 137:830S–7S. 
9. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics—
approaching a definition. Am J Clin Nutr (2001) 73:361s–4s. 
10. Lemon KP, Armitage GC, Relman DA, Fischbach MA. Microbiota-targeted 
therapies: an ecological perspective. Sci Transl Med (2012) 4:137rv5. 
doi:10.1126/scitranslmed.3004183 
11. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present 
and future. Curr Opin Gastroenterol (2013) 29:79–84. doi:10.1097/
MOG.0b013e32835a4b3e 
12. Klemashevich C, Wu C, Howsmon D, Alaniz RC, Lee K, Jayaraman A. 
Rational identification of diet-derived postbiotics for improving intestinal 
microbiota function. Curr Opin Biotechnol (2014) 26:85–90. doi:10.1016/j.
copbio.2013.10.006 
13. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and 
ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol (2006) 3:390–407. 
doi:10.1038/ncpgasthep0528 
14. Halfvarson J, Jess T, Magnuson A, Montgomery SM, Orholm M, Tysk C, 
et al. Environmental factors in inflammatory bowel disease: a co-twin con-
trol study of a Swedish-Danish twin population. Inflamm Bowel Dis (2006) 
12:925–33. doi:10.1097/01.mib.0000228998.29466.ac 
15. Dicksved J, Halfvarson J, Rosenquist M, Järnerot G, Tysk C, Apajalahti J, 
et al. Molecular analysis of the gut microbiota of identical twins with Crohn’s 
disease. ISME J (2008) 237:716–27. doi:10.1038/ismej.2008.37 
16. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, 
Gratadoux J-J, et  al. Faecalibacterium prausnitzii is an anti-inflammatory 
commensal bacterium identified by gut microbiota analysis of Crohn dis-
ease patients. Proc Natl Acad Sci U S A (2008) 105:16731–6. doi:10.1073/
pnas.0804812105 
17. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind com-
parison of an oral Escherichia coli preparation and mesalazine in maintaining 
remission of ulcerative colitis. Aliment Pharmacol Ther (1997) 11:853–8. 
doi:10.1046/j.1365-2036.1997.00225.x 
18. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, et al. Maintaining 
remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is 
as effective as with standard mesalazine. Gut (2004) 53:1617–23. doi:10.1136/
gut.2003.037747 
19. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. 
Non-pathogenic Escherichia coli versus mesalazine for the treatment of 
ulcerative colitis: a randomised trial. Lancet (1999) 354:635–9. doi:10.1016/
S0140-6736(98)06343-0 
20. Petersen AM, Mirsepasi H, Halkjaer SI, Mortensen EM, Nordgaard-Lassen I, 
Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on 
treatment in active ulcerative colitis: a double-blind randomized placebo 
controlled clinical trial. J Crohns Colitis (2014) 8:1498–505. doi:10.1016/j.
crohns.2014.06.001 
21. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: pro-
biotic treatment of acute distal ulcerative colitis with rectally administered 
Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med (2010) 
10:13. doi:10.1186/1472-6882-10-13 
22. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, et  al. 
Randomised clinical trial: the effectiveness of Lactobacillus reuteri 
ATCC 55730 rectal enema in children with active distal ulcerative colitis. 
Aliment Pharmacol Ther (2012) 35:327–34. doi:10.1111/j.1365-2036. 
2011.04939.x 
23. D’Incà R, Barollo M, Scarpa M, Grillo AR, Brun P, Vettorato MG, et  al. 
Rectal administration of Lactobacillus casei DG modifies flora composition 
and toll-like receptor expression in colonic mucosa of patients with mild 
ulcerative colitis. Dig Dis Sci (2011) 56:1178–87. doi:10.1007/s10620-010- 
1384-1 
24. Soo I, Madsen KL, Tejpar Q, Sydora BC, Sherbaniuk R, Cinque B, et  al. 
VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyeli-
nase and reduces inflammation. Can J Gastroenterol (2008) 22:237–42. 
doi:10.1155/2008/520383 
25. Wu J, Nilsson A, Jönsson BAG, Stenstad H, Agace W, Cheng Y, et al. Intestinal 
alkaline sphingomyelinase hydrolyses and inactivates platelet-activating 
factor by a phospholipase C activity. Biochem J (2006) 394:299–308. 
doi:10.1042/BJ20051121 
26. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. 
Effect of a probiotic preparation (VSL#3) on induction and maintenance 
of remission in children with ulcerative colitis. Am J Gastroenterol (2009) 
104:437–43. doi:10.1038/ajg.2008.118 
27. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. 
Low-dose balsalazide plus a high-potency probiotic preparation is more 
effective than balsalazide alone or mesalazine in the treatment of acute 
mild-to-moderate ulcerative colitis. Med Sci Monit (2004) 10:I126–31. 
28. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, et al. The 
probiotic preparation, VSL#3 induces remission in patients with mild-to- 
moderately active ulcerative colitis. Clin Gastroenterol Hepatol (2009) 7:1209.
e1. doi:10.1016/j.cgh.2009.07.016 
29. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et  al. 
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic 
12
Slingerland et al. Microbiome in Inflammatory Diseases
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 400
VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, 
randomized, placebo-controlled study. Am J Gastroenterol (2010) 105: 
2218–27. doi:10.1038/ajg.2010.218 
30. Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, et al. 
Immunosuppressive effects via human intestinal dendritic cells of probiotic 
bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm 
Bowel Dis (2010) 16:1286–98. doi:10.1002/ibd.21222 
31. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, et al. Randomized 
placebo-controlled trial assessing the effect of bifidobacteria-fermented milk 
on active ulcerative colitis. Aliment Pharmacol Ther (2004) 20:1133–41. 
doi:10.1111/j.1365-2036.2004.02268.x 
32. Cui H-H, Chen C-L, Wang J-D, Yang Y-J, Cun Y, Wu J-B, et al. Effects of 
probiotic on intestinal mucosa of patients with ulcerative colitis. World 
J Gastroenterol (2004) 10:1521–5. doi:10.3748/wjg.v10.i10.1521 
33. Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cyto-
kines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 
(2010) 16:4145–51. doi:10.3748/wjg.v16.i33.4145 
34. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised 
double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 
and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remis-
sion in ulcerative colitis. J Crohns Colitis (2011) 5:115–21. doi:10.1016/j.
crohns.2010.11.004 
35. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and 
prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr 
Soc (2007) 66:307–15. doi:10.1017/S0029665107005563 
36. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. 
Oral bacteriotherapy as maintenance treatment in patients with chronic 
pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 
119:305–9. doi:10.1053/gast.2000.9370 
37. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et  al. 
Once daily high dose probiotic therapy (VSL#3) for maintaining remission 
in recurrent or refractory pouchitis. Gut (2004) 53:108–14. doi:10.1136/
gut.53.1.108 
38. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, 
et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, 
placebo-controlled trial. Gastroenterology (2003) 124:1202–9. doi:10.1016/
S0016-5085(03)00171-9 
39. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, et al. 
Probiotic administration in patients with ileal pouch–anal anastomosis for 
ulcerative colitis is associated with expansion of mucosal regulatory cells. 
Inflamm Bowel Dis (2008) 14:662–8. doi:10.1002/ibd.20369 
40. Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, et al. 
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: 
experience in clinical practice. Aliment Pharmacol Ther (2005) 22:721–8. 
doi:10.1111/j.1365-2036.2005.02642.x 
41. Tomasz B, Zoran S, Jarosław W, Ryszard M, Marcin G, Robert B, et  al. 
Long-term use of probiotics Lactobacillus and Bifidobacterium has a 
prophylactic effect on the occurrence and severity of pouchitis: a ran-
domized prospective study. Biomed Res Int (2014) 2014:208064–208064. 
doi:10.1155/2014/208064 
42. Laake KO, Bjørneklett A, Bakka A, Midtvedt T, Norin KE, Eide TJ, et  al. 
Influence of fermented milk on clinical state, fecal bacterial counts and 
biochemical characteristics in patients with ileal-pouch-anal-anastomosis. 
Microb Ecol Health Dis (1999) 11:211–7. doi:10.1080/08910609908540830 
43. Brown SJ, Megan J, Smith S, Matchet D, Elliott R. Bifidobacterium longum 
BB-536 and prevention of acute pouchitis. Gastroenterology (2004) 
126:A465–465. 
44. Yasueda A, Mizushima T, Nezu R, Sumi R, Tanaka M, Nishimura J, et al. The 
effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and 
alteration of the microbiota profile in patients with ulcerative colitis. Surg 
Today (2016) 46:939–49. doi:10.1007/s00595-015-1261-9 
45. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of 
Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial 
flora. Aliment Pharmacol Ther (2003) 17:509–15. doi:10.1046/j.1365-2036. 
2003.01465.x 
46. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild 
residual symptoms in a stable phase of Crohn’s disease with special respect to 
chronic diarrhea – a pilot study. Z Gastroenterol (1993) 31:129–34. 
47. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in 
maintenance treatment of Crohn’s disease. Dig Dis Sci (2000) 45:1462–4. 
doi:10.1023/A:1005588911207 
48. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama 
Torres H, Guerra Pinto A, Carolina Carneiro Aguirre A, Paiva Martins F, 
et  al. Influence of Saccharomyces boulardii on the intestinal permeability 
of patients with Crohn’s disease in remission. Scand J Gastroenterol (2008) 
43:842–8. doi:10.1080/00365520801943354 
49. Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugerie L, Dupas JL, 
et  al. Saccharomyces boulardii does not prevent relapse of Crohn’s disease. 
Clin Gastroenterol Hepatol (2013) 11:982–7. doi:10.1016/j.cgh.2013.02.021 
50. Madsen K, Backer JL, Leddin D, Dieleman LA, Bitton A, Feagan B, et  al. 
M1207 A randomized controlled trial of VSL# 3 for the prevention of endo-
scopic recurrence following surgery for Crohn’s disease. Gastroenterology 
(2008) 134:A–361. doi:10.1016/S0016-5085(08)61682-0 
51. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness 
of probiotics in preventing recurrence after curative resection for Crohn’s 
disease: a randomised controlled trial with Lactobacillus GG. Gut (2002) 
51:405–9. doi:10.1136/gut.51.3.405 
52. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. 
Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. 
BMC Gastroenterol (2004) 4:5. doi:10.1186/1471-230X-4-5 
53. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, 
et  al. A randomized, double-blind trial of Lactobacillus GG versus 
placebo in addition to standard maintenance therapy for children with 
Crohn’s disease. Inflamm Bowel Dis (2005) 11:833–9. doi:10.1097/01.
MIB.0000175905.00212.2c 
54. Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, 
et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce 
endoscopic recurrence after surgery for Crohn’s disease. Clin Gastroenterol 
Hepatol (2015) 13:928.e–35.e. doi:10.1016/j.cgh.2014.10.031 
55. Willert RP, Peddi KK, Ombiga J, Bampton PA, Lawrance IC. T1235 ran-
domised, double-blinded, placebo-controlled study of VSL#3 versus placebo 
in the maintenance of remission in Crohns disease. Gastroenterology (2010) 
138:S–517–S–518. doi:10.1016/S0016-5085(10)62390-6 
56. Malchow HA. Crohn’s disease and Escherichia coli. A new approach in ther-
apy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 
(1997) 25:653–8. doi:10.1097/00004836-199712000-00021 
57. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, 
et  al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of 
postoperative recurrence in Crohn’s disease: a randomised, double blind, 
placebo controlled GETAID trial. Gut (2006) 55:842–7. doi:10.1136/
gut.2005.076604 
58. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, et al. 
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus 
johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after 
lleo-caecal resection. Inflamm Bowel Dis (2007) 13:135–42. doi:10.1002/
ibd.20063 
59. Chiba M, Tsuji T, Nakane K, Komatsu M. High amount of dietary fiber 
not harmful but favorable for Crohn disease. Perm J (2015) 19:58–61. 
doi:10.7812/TPP/14-124 
60. Hanai H, Kanauchi O, Mitsuyama K, Andoh A, Takeuchi K, Takayuki I, et al. 
Germinated barley foodstuff prolongs remission in patients with ulcerative 
colitis. Int J Mol Med (2004) 13:643–7. 
61. Hafer A, Krämer S, Duncker S, Krüger M, Manns MP, Bischoff SC. Effect of 
oral lactulose on clinical and immunohistochemical parameters in patients 
with inflammatory bowel disease: a pilot study. BMC Gastroenterol (2007) 
7:36. doi:10.1186/1471-230X-7-36 
62. Lindsay J, Whelan K, Stagg A, Gobin P, Al-Hassi H, Rayment N, et  al. 
Clinical, microbiological, and immunological effects of fructo-oligosaccha-
ride in patients with Crohn’s disease. Gut (2006) 55:348–55. doi:10.1136/
gut.2005.074971 
63. Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, 
et  al. Randomised, double-blind, placebo-controlled trial of fructo-oligo-
saccharides in active Crohn’s disease. Gut (2011) 60:923–9. doi:10.1136/
gut.2010.232025 
64. Casellas F, Borruel N, TorrejÓN A, Varela E, Antolin M, Guarner F, et al. Oral 
oligofructose-enriched inulin supplementation in acute ulcerative colitis 
13
Slingerland et al. Microbiome in Inflammatory Diseases
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 400
is well tolerated and associated with lowered faecal calprotectin. Aliment 
Pharmacol Ther (2007) 25:1061–7. doi:10.1111/j.1365-2036.2007.03288.x 
65. Welters CF, Heineman E, Thunnissen FB, van den Bogaard AE, Soeters PB, 
Baeten CG. Effect of dietary inulin supplementation on inflammation of 
pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon 
Rectum (2002) 45:621–7. doi:10.1007/s10350-004-6257-2 
66. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointes-
tinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol (1991) 
26:747–50. doi:10.3109/00365529108998594 
67. Fernández-Bañares F, Hinojosa J, Sánchez-Lombrañ JL, Navarro E, Martínez-
Salmerón JF, García-Pugés A, et al. Randomized clinical trial of Plantago ovata 
seeds (dietary fiber) as compared with mesalamine in maintaining remission 
in ulcerative colitis for the Spanish group for the study of Crohn’s disease 
and ulcerative colitis (GETECCU). Am J Gastroenterol (1999) 94(2):427–33. 
doi:10.1111/j.1572-0241.1999.872_a.x 
68. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’Neil DA, 
et al. Synbiotic therapy (Bifidobacterium longum/synergy 1) initiates resolu-
tion of inflammation in patients with active ulcerative colitis: a randomised 
controlled pilot trial. Gut (2005) 54:242–9. doi:10.1136/gut.2004.044834 
69. Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y, et al. 
Beneficial effects of probiotic Bifidobacterium and galacto-oligosaccharide 
in patients with ulcerative colitis: a randomized controlled study. Digestion 
(2011) 84:128–33. doi:10.1159/000322977 
70. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, et al. Failure 
of synbiotic 2000 to prevent postoperative recurrence of Crohn’s disease. Dig 
Dis Sci (2007) 52:385–9. doi:10.1007/s10620-006-9549-7 
71. Suskind D, Wahbeh G, Vendetoulli H, Singh N, Crohn’s SM. Tu1754 fecal 
microbial transplant in pediatric Crohn’s disease. Gastroenterology (2014) 
146:S–834. doi:10.1016/S0016-5085(14)63030-4 
72. Suskind DL, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X, et al. 
Fecal microbial transplant effect on clinical outcomes and fecal microbiome 
in active Crohn’s disease. Inflamm Bowel Dis (2015) 21:556. doi:10.1097/
MIB.0000000000000307 
73. Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, et al. Fecal microbiota trans-
plantation through mid-gut for refractory Crohn’s disease: safety, feasibility, 
and efficacy trial results. J Gastroenterol Hepatol (2015) 30:51–8. doi:10.1111/
jgh.12727 
74. Vermeire S, Joossens M, Verbeke K, Hildebrand F, Machiels K, Van den 
Broeck K, et al. Sa1922 pilot study on the safety and efficacy of faecal micro-
biota transplantation in refractory Crohn’s disease. Gastroenterology (2012) 
142:S–360. doi:10.1016/S0016-5085(12)61356-0 
75. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, 
Papay P, et al. Temporal bacterial community dynamics vary among ulcerative 
colitis patients after fecal microbiota transplantation. Am J Gastroenterol 
(2013) 108:1620–30. doi:10.1038/ajg.2013.257 
76. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad  H Jr, et al. Safety, 
tolerability, and clinical response after fecal transplantation in children and 
young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr (2013) 
56:597–601. doi:10.1097/MPG.0b013e318292fa0d 
77. Wei Y, Zhu W, Gong J, Guo D, Gu L, Li N, et  al. Fecal microbiota 
transplantation improves the quality of life in patients with inflam-
matory bowel disease. Gastroenterol Res Pract (2015) 2015:517597. 
doi:10.1155/2015/517597 
78. Kao D, Madsen K. Fecal microbiota transplantation (FMT) in the treatment 
of inflammatory bowel disease (IBD): a case report. Am J Gastroenterol 
(2013) 108:S415–6. doi:10.1038/ajg.2013.267
79. Ren R, Sun G, Yang Y, Peng L, Zhang X, Wang S, et  al. [A pilot study of 
treating ulcerative colitis with fecal microbiota transplantation]. Zhonghua 
Nei Ke Za Zhi (2015) 54:411–5. 
80. Scaldaferri F, Pecere S, Bruno G, Ianiro G, Laterza L, Gerardi V, et  al. 
An open-label, pilot study to assess feasibility and safety of fecal 
microbiota transplantation in patients with mild-moderate ulcerative 
colitis: preliminary results. Gastroenterology (2015) 148:S870. doi:10.1016/
S0016-5085(15)32950-4 
81. Kump PK, Gröchenig H-P, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, 
et  al. Alteration of intestinal dysbiosis by fecal microbiota transplantation 
does not induce remission in patients with chronic active ulcerative colitis. 
Inflamm Bowel Dis (2013) 19:2155–65. doi:10.1097/MIB.0b013e31829ea325 
82. Damman C, Brittnacher M, Hayden H, Radey M, Hager K, Miller S, 
et  al. Su1403 single colonoscopically administered fecal microbiota 
transplant for ulcerative colitis-a pilot study to determine therapeutic 
benefit and graft stability. Gastroenterology (2014) 146:S–460. doi:10.1016/
S0016-5085(14)61646-2 
83. Damman CJ, Brittnacher MJ, Westerhoff M, Hayden HS, Radey M, Hager KR, 
et al. Low level engraftment and improvement following a single colonoscopic 
administration of fecal microbiota to patients with ulcerative colitis. PLoS 
One (2015) 10:e0133925. doi:10.1371/journal.pone.0133925 
84. Borody T, Wettstein A, Campbell J, Leis S, Torres M, Finlayson S, et al. Fecal 
microbiota transplantation in ulcerative colitis: review of 24 years experience. 
Am J Gastroenterol (2012) 107:S665. doi:10.1038/ajg.2012.275
85. Borody T, Campbell J, Torres M, Nowak A, Leis S. Reversal of idiopathic 
thrombocytopenic purpura [ITP] with fecal microbiota transplantation 
[FMT]. Am J Gastroenterol (2011) 106:S352. doi:10.1038/ajg.2011.336_7
86. Vaughn BP, Gevers D, Ting A, Korzenik JR, Robson SC, Moss AC. 
Mo1228 fecal microbiota transplantation induces early improvement in 
symptoms in patients with active Crohn’s disease. Gastroenterology (2014) 
146:S–591–S–592. doi:10.1016/S0016-5085(14)62143-0 
87. Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, et  al. 
Increased intestinal microbial diversity following fecal microbiota transplant 
for active Crohn’s disease. Inflamm Bowel Dis (2016) 22:2182–90. doi:10.1097/
MIB.0000000000000893 
88. Kellermayer R, Nagy-Szakal D, Harris RA, Luna RA, Pitashny M, Schady D, 
et al. Serial fecal microbiota transplantation alters mucosal gene expression in 
pediatric ulcerative colitis. Am J Gastroenterol (2015) 110:604–6. doi:10.1038/
ajg.2015.19 
89. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. 
Fecal microbiota transplantation induces remission in patients with active 
ulcerative colitis in a randomized controlled trial. Gastroenterology (2015) 
149:102–9. doi:10.1053/j.gastro.2015.04.001 
90. Rossen NG, Fuentes S, Van Der Spek MJ, Tijssen JG, Hartman JHA, Duflou A, 
et  al. Findings from a randomized controlled trial of fecal transplantation 
for patients with ulcerative colitis. Gastroenterology (2015) 149:110–8. 
doi:10.1053/j.gastro.2015.03.045 
91. Choi J, Chung SW, Kim SJ, Kim SJ. Establishment of Porphyromonas gingiva-
lis-specific T-cell lines from atherosclerosis patients. Oral Microbiol Immunol 
(2001) 16:316–8. doi:10.1034/j.1399-302x.2001.016005316.x 
92. Mosorin M, Surcel HM, Laurila A, Lehtinen M, Karttunen R, Juvonen J, 
et al. Detection of Chlamydia pneumoniae-reactive T lymphocytes in human 
atherosclerotic plaques of carotid artery. Arterioscler Thromb Vasc Biol (2000) 
20:1061–7. doi:10.1161/01.ATV.20.4.1061 
93. Marques da Silva R, Lingaas PS, Geiran O, Tronstad L, Olsen I. Multiple 
bacteria in aortic aneurysms. J Vasc Surg (2003) 38:1384–9. doi:10.1016/
S0741-5214(03)00926-1 
94. Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, 
et  al. Behcet’s syndrome patients exhibit specific microbiome signature. 
Autoimmun Rev (2015) 14:269–76. doi:10.1016/j.autrev.2014.11.009 
95. Saadoun D, Terrier B, Semoun O, Sene D, Maisonobe T, Musset L, et  al. 
Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res 
(Hoboken) (2011) 63:427–35. doi:10.1002/acr.20381 
96. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in cor-
onary arterial fatty streaks and atheromatous plaques. S Afr Med J (1992) 
82:158–61. 
97. Kalayoglu MV, Perkins BN, Byrne GI. Chlamydia pneumoniae-infected 
monocytes exhibit increased adherence to human aortic endothelial cells. 
Microbes Infect (2001) 3:963–9. doi:10.1016/S1286-4579(01)01458-7 
98. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et  al. 
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, 
promotes atherosclerosis. Nat Med (2013) 19:576–85. doi:10.1038/ 
nm.3145 
99. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial 
metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. 
Cell (2016) 165:111–24. doi:10.1016/j.cell.2016.02.011 
100. Bhatt AS, Manzo VE, Pedamallu CS, Duke F, Cai D, Bienfang DC, et al. In 
search of a candidate pathogen for giant cell arteritis: sequencing-based 
characterization of the giant cell arteritis microbiome. Arthritis Rheumatol 
(2014) 66:1939–44. doi:10.1002/art.38631 
14
Slingerland et al. Microbiome in Inflammatory Diseases
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 400
101. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et  al. 
Topographical and temporal diversity of the human skin microbiome. 
Science (2009) 324:1190–2. doi:10.1126/science.1171700 
102. Bieber T. Atopic dermatitis. N Engl J Med (2008) 358:1483–94. doi:10.1056/
NEJMra074081 
103. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal 
shifts in the skin microbiome associated with disease flares and treatment in 
children with atopic dermatitis. Genome Res (2012) 22:850–9. doi:10.1101/
gr.131029.111 
104. Nakamura Y, Oscherwitz J, Cease KB, Chan SM, Munoz-Planillo R, Hasegawa M, 
et  al. Staphylococcus delta-toxin induces allergic skin disease by activating 
mast cells. Nature (2013) 503:397–401. doi:10.1038/nature12655 
105. Fry L, Baker BS, Powles AV, Engstrand L. Psoriasis is not an autoimmune 
disease? Exp Dermatol (2015) 24:241–4. doi:10.1111/exd.12572 
106. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of 
the cutaneous bacterial biota in psoriatic lesions. PLoS One (2008) 3:e2719. 
doi:10.1371/journal.pone.0002719 
107. Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial 
microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol 
Res (2012) 304:15–22. doi:10.1007/s00403-011-1189-x 
108. Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, et  al. 
Antibiotic exposure, infection, and the development of pediatric psoriasis: 
a nested case-control study. JAMA Dermatol (2016) 152:191–9. doi:10.1001/
jamadermatol.2015.3650 
109. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of 
systemic sclerosis. Annu Rev Pathol (2011) 6:509–37. doi:10.1146/
annurev-pathol-011110-130312 
110. Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, 
et al. The role of infections in the immunopathogensis of systemic sclerosis – 
evidence from serological studies. Ann N Y Acad Sci (2009) 1173:627–32. 
doi:10.1111/j.1749-6632.2009.04808.x 
111. Grossman C, Dovrish Z, Shoenfeld Y, Amital H. Do infections facilitate 
the emergence of systemic sclerosis? Autoimmun Rev (2011) 10:244–7. 
doi:10.1016/j.autrev.2010.09.010 
112. Arron ST, Dimon MT, Li Z, Johnson ME, Wood TA, Feeney L, et al. High 
Rhodotorula sequences in skin transcriptome of patients with diffuse 
systemic sclerosis. J Invest Dermatol (2014) 134:2138–45. doi:10.1038/jid. 
2014.127 
113. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut 
microbiomes are perturbed in rheumatoid arthritis and partly normalized 
after treatment. Nat Med (2015) 21:895–905. doi:10.1038/nm.3914 
114. Liu X, Zou Q, Zeng B, Fang Y, Wei H. Analysis of fecal Lactobacillus com-
munity structure in patients with early rheumatoid arthritis. Curr Microbiol 
(2013) 67:170–6. doi:10.1007/s00284-013-0338-1 
115. Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, Sharif SK, Asghari-
Jafarabadi M, Zavvari S. Probiotic supplementation improves inflammatory 
status in patients with rheumatoid arthritis. Nutrition (2014) 30:430–5. 
doi:10.1016/j.nut.2013.09.007 
116. Reichert S, Haffner M, Keysser G, Schafer C, Stein JM, Schaller HG, et al. 
Detection of oral bacterial DNA in synovial fluid. J Clin Periodontol (2013) 
40:591–8. doi:10.1111/jcpe.12102 
117. Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, et al. Periodontal 
disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis 
Rheum (2012) 64:3083–94. doi:10.1002/art.34539 
118. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et  al. 
Expansion of intestinal Prevotella copri correlates with enhanced susceptibil-
ity to arthritis. Elife (2013) 2:e01202. doi:10.7554/eLife.01202 
119. Busse WW, Lemanske  RF Jr. Asthma. N Engl J Med (2001) 344:350–62. 
doi:10.1056/NEJM200102013440507 
120. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered 
microbial communities in asthmatic airways. PLoS One (2010) 5:e8578. 
doi:10.1371/journal.pone.0008578 
121. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bonnelykke K, 
et al. Childhood asthma after bacterial colonization of the airway in neonates. 
N Engl J Med (2007) 357:1487–95. doi:10.1056/NEJMoa052632 
122. Marri PR, Stern DA, Wright AL, Billheimer D, Martinez FD. Asthma-
associated differences in microbial composition of induced sputum. J Allergy 
Clin Immunol (2013) 131:e1–3. doi:10.1016/j.jaci.2012.11.013 
123. Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, Hall CF, 
et  al. The effects of airway microbiome on corticosteroid responsiveness 
in asthma. Am J Respir Crit Care Med (2013) 188:1193–201. doi:10.1164/
rccm.201304-0775OC 
124. Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Muller G, et al. 
Reduced diversity of the intestinal microbiota during infancy is associated 
with increased risk of allergic disease at school age. J Allergy Clin Immunol 
(2011) 128:.e1–5. doi:10.1016/j.jaci.2011.04.060 
125. Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand 
L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes 
asthma at school age. Clin Exp Allergy (2014) 44:842–50. doi:10.1111/cea. 
12253 
126. Arrieta MC, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, 
et al. Early infancy microbial and metabolic alterations affect risk of child-
hood asthma. Sci Transl Med (2015) 7:307ra152. doi:10.1126/scitranslmed.
aab2271 
127. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of 
the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol (2009) 
6:306–14. doi:10.1038/nrgastro.2009.35 
128. Hohlfeld R. Multiple sclerosis: human model for EAE? Eur J Immunol (2009) 
39:2036–9. doi:10.1002/eji.200939545 
129. Dimachkie MM, Barohn RJ.  Guillain-barré syndrome and variants. 
Neurologic Clinics (2013) 31(2):491–510. doi:10.1016/j.ncl.2013.01.005
130. Oksenberg JR. Decoding multiple sclerosis: an update on genomics and 
future directions. Expert Rev Neurother (2013) 13:11–9. doi:10.1586/14737
175.2013.865867 
131. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, et  al. 
Commensal microbiota and myelin autoantigen cooperate to trigger auto-
immune demyelination. Nature (2011) 479:538–41. doi:10.1038/nature10554 
132. Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, et  al. 
Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a 
striking depletion of species belonging to Clostridia XIVa and IV clusters. 
PLoS One (2015) 10:e0137429. doi:10.1371/journal.pone.0137429 
133. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Soldan MMP, et al. Multiple 
sclerosis patients have a distinct gut microbiota compared to healthy controls. 
Sci Rep (2016) 6:28484–28484. doi:10.1038/srep28484 
134. Buscarinu MC, Cerasoli B, Annibali V, Policano C, Lionetto L, Capi 
M, et  al. Altered intestinal permeability in patients with relapsing- 
remitting multiple sclerosis: a pilot study. Mult Scler (2016) 23(3):442–6. 
doi:10.1177/1352458516652498 
135. Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, 
et  al. Gut microbiota in multiple sclerosis. J Invest Med (2015) 63:729–34. 
doi:10.1097/JIM.0000000000000192 
136. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, et al. Alterations of the 
human gut microbiome in multiple sclerosis. Nat Commun (2016) 7:12015. 
doi:10.1038/ncomms12015 
137. Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, et  al. 
Associations between the gut microbiota and host immune markers in pedi-
atric multiple sclerosis and controls. BMC Neurol (2016) 16:182. doi:10.1186/
s12883-016-0703-3 
138. Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, et  al. 
Gut microbiota composition and relapse risk in pediatric MS: a pilot study. 
J Neurol Sci (2016) 363:153–7. doi:10.1016/j.jns.2016.02.042 
139. Rumah KR, Linden J, Fischetti VA, Vartanian T. Isolation of Clostridium 
perfringens type B in an individual at first clinical presentation of multiple 
sclerosis provides clues for environmental triggers of the disease. PLoS One 
(2013) 8:e76359. doi:10.1371/journal.pone.0076359 
140. Borody T, Leis S, Campbell J, Torres M, Nowak A. Fecal microbiota trans-
plantation (FMT) in multiple sclerosis (MS). Am J Gastroenterol (2011) 
106:S352. doi:10.1038/ajg.2011.336_7 
141. Correale J, Farez M. Association between parasite infection and immune 
responses in multiple sclerosis. Ann Neurol (2007) 61:97–108. doi:10.1002/
ana.21067 
142. Fleming JO, Isaak A, Lee JE, Luzzio CC, Carrithers MD, Cook TD, et  al. 
Probiotic helminth administration in relapsing-remitting multiple sclerosis: 
a phase 1 study. Mult Scler (2011) 17:743–54. doi:10.1177/1352458511398054 
143. Lee SC, Tang MS, Lim YAL, Choy SH, Kurtz ZD, Cox LM, et al. Helminth 
colonization is associated with increased diversity of the gut microbiota. PLoS 
Negl Trop Dis (2014) 8:e2880. doi:10.1371/journal.pntd.0002880 
144. Kaldor J, Speed BR. Guillain-Barre syndrome and Campylobacter 
jejuni: a serological study. Br Med J (1984) 288:1867–70. doi:10.1136/
bmj.288.6434.1867 
15
Slingerland et al. Microbiome in Inflammatory Diseases
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 400
145. Winer JB, Hughes RAC, Anderson MJ, Jones DM, Kangro H, Watkinsii F. 
A prospective study of acute idiopathic neuropathy. II. Antecedent events. 
J Neurol Neurosurg Psychiatry (1988) 51:613–8. doi:10.1136/jnnp.51.5.613 
146. Mishu B. Serologic evidence of previous Campylobacter jejuni infection 
in patients with the Guillain-Barre syndrome. Ann Intern Med (1993) 
118:947–947. doi:10.7326/0003-4819-118-12-199306150-00006 
147. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni 
infection and Guillain-Barré syndrome. N Engl J Med (1995) 333:1374–9. 
doi:10.1056/NEJM199511233332102 
148. Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, et  al. 
Campylobacter jejuni strains from patients with Guillain-Barré syndrome 
belong mostly to penner serogroup 19 and contain β-N-acetylglucosamine 
residues. Ann Neurol (2004) 33:243–7. doi:10.1002/ana.410330304 
149. Pham TAN, Lawley TD. Emerging insights on intestinal dysbiosis during 
bacterial infections. Curr Opin Microbiol (2014) 17:67–74. doi:10.1016/j.
mib.2013.12.002 
150. Goldenberg DL. Fibromyalgia syndrome: an emerging but controversial con-
dition. JAMA (1987) 257:2782–7. doi:10.1001/jama.1987.03390200122026 
151. Wallace D, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman M. 
Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot 
study. Rheumatology (2001) 40:743–9. doi:10.1093/rheumatology/40.7.743 
152. Goebel A, Buhner S, Schedel R, Lochs H, Sprotte G. Altered intestinal 
permeability in patients with primary fibromyalgia and in patients with 
complex regional pain syndrome. Rheumatology (Oxford) (2008) 47:1223–7. 
doi:10.1093/rheumatology/ken140 
153. Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory 
bowel disease. J Rheumatol (1999) 26:1167–71. 
154. Veale D, Kavanagh G, Fielding JF, Fitzgerald O. Primary fibromyalgia and the 
irritable bowel syndrome: different expressions of a common pathogenetic 
process. Rheumatology (1991) 30:220–2. doi:10.1093/rheumatology/30.3.220 
155. Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibro-
myalgia syndrome. Dig Dis Sci (1991) 36:59–64. doi:10.1007/BF01300088 
156. Sivri A, Cindaş A, Dinçer F, Sivri B. Bowel dysfunction and irritable bowel 
syndrome in fibromyalgia patients. Clin Rheumatol (1996) 15:283–6. 
doi:10.1007/BF02229708 
157. Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, 
et  al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence 
and clinical implications. Am J Gastroenterol (1999) 94:3541–6. doi:10.1111/ 
j.1572-0241.1999.01643.x 
158. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, et al. A link 
between irritable bowel syndrome and fibromyalgia may be related to findings 
on lactulose breath testing. Ann Rheum Dis (2004) 63:450–2. doi:10.1136/
ard.2003.011502 
159. Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 
(2003) 56:481–90. doi:10.1136/jcp.56.7.481 
160. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in 
systemic lupus erythematosus: more than 100 different antibodies found 
in SLE patients. Semin Arthritis Rheum (2004) 34:501–37. doi:10.1016/j.
semarthrit.2004.07.002 
161. Hevia A, Milani C, López P, Cuervo A, Arboleya S, Duranti S, et al. Intestinal 
dysbiosis associated with systemic lupus erythematosus. MBio (2014) 
5:e1548–1514. doi:10.1128/mBio.01548-14 
162. Rojo D, Hevia A, Bargiela R, López P, Cuervo A, González S, et al. Ranking 
the impact of human health disorders on gut metabolism: systemic lupus 
erythematosus and obesity as study cases. Sci Rep (2015) 5:8310–8310. 
doi:10.1038/srep08310 
163. López P, de Paz B, Rodríguez-Carrio J, Hevia A, Sánchez B, Margolles A, 
et al. Th17 responses and natural IgM antibodies are related to gut micro-
biota composition in systemic lupus erythematosus patients. Sci Rep (2016) 
6:24072–24072. doi:10.1038/srep24072 
164. Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, et  al. 
Graft-versus-host disease and survival in patients with aplastic anemia 
treated by marrow grafts from HLA-identical siblings. Beneficial effect of 
a protective environment. N Engl J Med (1983) 308:302–7. doi:10.1056/
NEJM198302103080602 
165. Vossen JM, Guiot HF, Lankester AC, Vossen AC, Bredius RG, Wolterbeek R, 
et  al. Complete suppression of the gut microbiome prevents acute graft-
versus-host disease following allogeneic bone marrow transplantation. PLoS 
One (2014) 9:e105706. doi:10.1371/journal.pone.0105706 
166. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of 
intestinal bacterial decontamination using metronidazole and ciprofloxacin 
or ciprofloxacin alone on the development of acute graft-versus-host disease 
after marrow transplantation in patients with hematologic malignancies: final 
results and long-term follow-up of an open-label prospective randomized 
trial. Blood (1999) 93:3267–75. 
167. Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, et  al. 
Regulation of intestinal inflammation by microbiota following allogeneic 
bone marrow transplantation. J Exp Med (2012) 209:903–11. doi:10.1084/
jem.20112408 
168. Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, 
et  al. Metagenomic analysis of the stool microbiome in patients receiving 
allogeneic stem cell transplantation: loss of diversity is associated with use of 
systemic antibiotics and more pronounced in gastrointestinal graft-versus-
host disease. Biol Blood Marrow Transplant (2014) 20:640–5. doi:10.1016/j.
bbmt.2014.01.030 
169. Biagi E, Zama D, Nastasi C, Consolandi C, Fiori J, Rampelli S, et  al. 
Gut microbiota trajectory in pediatric patients undergoing hemato-
poietic SCT. Bone Marrow Transplant (2015) 50:992–8. doi:10.1038/
bmt.2015.16 
170. Simms-Waldrip T, Meir M, Fan D, Coughlin L, Savani M, Watt T, et al. The 
role of gut microbiota in the development of intestinal GVHD. Biol Blood 
Marrow Transplant (2014) 20:S55–6. doi:10.1016/j.bbmt.2013.12.060 
171. Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, et al. Intestinal 
Blautia is associated with reduced death from graft-versus-host disease. 
Biol Blood Marrow Transplant (2015) 21:1373–83. doi:10.1016/j.bbmt.2015. 
04.016 
172. Weber D, Oefner PJ, Hiergeist A, Koestler J, Gessner A, Weber M, et al. Low 
urinary indoxyl sulfate levels early after transplantation reflect a disrupted 
microbiome and are associated with poor outcome. Blood (2015) 126:1723–8. 
doi:10.1182/blood-2015-04-638858 
173. Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, et  al. 
Increased GVHD-related mortality with broad-spectrum antibiotic use after 
allogeneic hematopoietic stem cell transplantation in human patients and 
mice. Sci Transl Med (2016) 8:339ra71. doi:10.1126/scitranslmed.aaf2311 
174. Weber D, Oefner PJ, Dettmer K, Hiergeist A, Koestler J, Gessner A, et  al. 
Rifaximin preserves intestinal microbiota balance in patients undergoing 
allogeneic stem cell transplantation. Bone Marrow Transplant (2016) 
51:1087–92. doi:10.1038/bmt.2016.66 
175. Kakihana K, Fujioka Y, Suda W, Najima Y, Kuwata G, Sasajima S, et al. Fecal 
microbiota transplantation for patients with steroid-resistant/dependent 
acute graft-versus-host disease of the gut. Blood (2016) 128(16):2083–8. 
doi:10.1182/blood-2016-05-717652 
Conflict of Interest Statement: RRJ is on the board of directors or an advisory 
committee for Seres Therapeutics, Inc.; has consulted for Ziopharm Oncology; and 
holds patents with or receives royalties from Seres Therapeutics, Inc. The other 
authors declare no conflict of interest.
Copyright © 2017 Slingerland, Schwabkey, Wiesnoski and Jenq. This is an open- 
access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permit-
ted, provided the original author(s) or licensor are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with 
these terms.
